Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of lanadelumab for prevention of attacks in non-histaminergic angioedema with normal C1 inhibitor
NL-OMON50984Phase 3Active, not recruiting
- Sponsor
- Takeda
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lanadelumab in angioedema, sponsored by Takeda. Primary endpoint: Long-term safety. Started Mar 2022; status: active, not recruiting.
02
Drugs
lanadelumab
03
Conditions
angioedema
Beyond the preview
Go deeper on NL-OMON50984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50984.